T1	p 246 284	patients with asthma poorly controlled
T2	p 691 709	adult asthmatics .
T3	p 718 741	Sixty-six subjects were
T4	p 763 767	FP/M
T5	p 772 780	12 weeks
T6	i 6 91	Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast
T7	i 305 320	corticosteroids
T8	i 433 451	placebo-controlled
T9	i 504 601	salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M )
T10	i 763 767	FP/M
T11	i 1386 1390	FP/M
T12	o 153 172	airway inflammation
T13	o 395 409	inflammation .
T14	o 602 687	on sputum inflammatory markers , airway responsiveness , lung function , and symptoms
T15	o 807 927	changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum . Additional
T16	o 950 1067	change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .
T17	o 1121 1156	induced sputum inflammatory cells ,
T18	o 1190 1223	reduction in sputum eosinophils .
T19	o 1263 1284	airway responsiveness
T20	o 1340 1373	symptom control and lung function
T21	o 1420 1463	reductions in sputum cysteinyl leukotrienes
T22	o 1575 1607	eosinophilic airway inflammation
T23	o 1619 1634	PEF and symptom